
## Rosaria Gangemi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1751919/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	In uveal melanoma Gα-protein GNA11 mutations convey a shorter disease-specific survival and are more strongly associated with loss of BAP1 and chromosomal alterations than Gα-protein GNAQ mutations. European Journal of Cancer, 2022, 170, 27-41.	2.8	15
2	Identification of histone deacetylase inhibitors with (arylidene)aminoxy scaffold active in uveal melanoma cell lines. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 34-47.	5.2	11
3	How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma. Cancers, 2021, 13, 2043.	3.7	18
4	Uveal Melanoma Metastasis. Cancers, 2021, 13, 5684.	3.7	24
5	Antiproliferative and apoptotic activity of new indazole derivatives as potential anticancer agents. Archiv Der Pharmazie, 2020, 353, 2000173.	4.1	2
6	Potential Onco-Suppressive Role of miR122 and miR144 in Uveal Melanoma through ADAM10 and C-Met Inhibition. Cancers, 2020, 12, 1468.	3.7	14
7	3-Aryl-4-nitrobenzothiochromans S,S-dioxide: From Calcium-Channel Modulators Properties to Multidrug-Resistance Reverting Activity. Molecules, 2020, 25, 1056.	3.8	7
8	Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives. Cancers, 2019, 11, 846.	3.7	66
9	Synthesis and Antiâ€proliferative Activity of Novel Polysubstitued Indazole Derivatives. Journal of Heterocyclic Chemistry, 2019, 56, 343-348.	2.6	5
10	The biology of uveal melanoma. Cancer and Metastasis Reviews, 2017, 36, 109-140.	5.9	160
11	IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient Small Cell Lung Cancer cells. Journal of Experimental and Clinical Cancer Research, 2017, 36, 140.	8.6	19
12	A highly invasive subpopulation of MDA-MB-231 breast cancer cells shows accelerated growth, differential chemoresistance, features of apocrine tumors and reduced tumorigenicity <i>in vivo</i> . Oncotarget, 2016, 7, 68803-68820.	1.8	30
13	Potentiation of cisplatin-induced antiproliferative and apoptotic activities by the antiarrhythmic drug procainamide hydrochloride. Pharmacological Reports, 2016, 68, 654-661.	3.3	2
14	Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma. JAMA Ophthalmology, 2015, 133, 1013.	2.5	48
15	CD133-Positive Cells from Non-Small Cell Lung Cancer Show Distinct Sensitivity to Cisplatin and Afatinib. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 207-214.	2.3	15
16	Human Renal Normal, Tumoral, and Cancer Stem Cells Express Membrane-Bound Interleukin-15 Isoforms Displaying Different Functions. Neoplasia, 2015, 17, 509-517.	5.3	10
17	Folate–Cyclodextrin Conjugates as Carriers of the Platinum(IV) Complex LAâ€12. ChemPlusChem, 2015, 80, 536-543.	2.8	9
18	<scp>ADAM</scp> 10 correlates with uveal melanoma metastasis and promotes in vitro invasion. Pigment Cell and Melanoma Research, 2014, 27, 1138-1148.	3.3	25

Rosaria Gangemi

#	Article	IF	CITATIONS
19	Synthesis and Antitumor Activity of Some Substituted Indazole Derivatives. Archiv Der Pharmazie, 2014, 347, 423-431.	4.1	39
20	Glycosylated copper( <scp>ii</scp> ) ionophores as prodrugs for β-glucosidase activation in targeted cancer therapy. Dalton Transactions, 2013, 42, 2023-2034.	3.3	57
21	Evaluation of the anti-proliferative activity of three new pyrazole compounds in sensitive and resistant tumor cell lines. Pharmacological Reports, 2013, 65, 717-723.	3.3	10
22	ABCB1 Structural Models, Molecular Docking, and Synthesis of New Oxadiazolothiazin-3-one Inhibitors. ACS Medicinal Chemistry Letters, 2013, 4, 694-698.	2.8	16
23	Synthesis, antiproliferative and apoptotic activities ofÂN-(6(4)-indazolyl)-benzenesulfonamide derivatives as potential anticancerÂagents. European Journal of Medicinal Chemistry, 2012, 57, 240-249.	5.5	60
24	Mda-9/Syntenin Is Expressed in Uveal Melanoma and Correlates with Metastatic Progression. PLoS ONE, 2012, 7, e29989.	2.5	64
25	Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?. Drug Discovery Today, 2012, 17, 435-442.	6.4	31
26	New Perspectives in Glioma Immunotherapy. Current Pharmaceutical Design, 2011, 17, 2439-2467.	1.9	23
27	Synthesis and biological evaluation of novel pyrazole derivatives with anticancer activity. European Journal of Medicinal Chemistry, 2011, 46, 5293-5309.	5.5	125
28	<i>SOX2</i> Silencing in Glioblastoma Tumor-Initiating Cells Causes Stop of Proliferation and Loss of Tumorigenicity. Stem Cells, 2009, 27, 40-48.	3.2	521
29	Cancer Stem Cells: A New Paradigm for Understanding Tumor Growth and Progression and Drug Resistance. Current Medicinal Chemistry, 2009, 16, 1688-1703.	2.4	124
30	Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses. International Journal of Cancer, 2007, 121, 1756-1763.	5.1	43
31	Effects of <i>Emx2</i> inactivation on the gene expression profile of neural precursors. European Journal of Neuroscience, 2006, 23, 325-334.	2.6	36
32	Regulatory genes controlling cell fate choice in embryonic and adult neural stem cells. Journal of Neurochemistry, 2004, 89, 1056-1056.	3.9	1
33	Regulatory genes controlling cell fate choice in embryonic and adult neural stem cells. Journal of Neurochemistry, 2004, 89, 286-306.	3.9	31
34	Emx2 Promotes Symmetric Cell Divisions and a Multipotential Fate in Precursors from the Cerebral Cortex. Molecular and Cellular Neurosciences, 2001, 18, 485-502.	2.2	105
35	Emx2 in adult neural precursor cells. Mechanisms of Development, 2001, 109, 323-329.	1.7	45
36	Late apoptotic effects of taxanes on K562 erythroleukemia cells: Apoptosis is delayed upstream of caspaseâ€3 activation. International Journal of Cancer, 2000, 85, 527-533.	5.1	18

**ROSARIA GANGEMI** 

#	Article	IF	CITATIONS
37	Biological Parameters in Breast Cancer. Annals of the New York Academy of Sciences, 1996, 784, 521-524.	3.8	о
38	Apoptosis Susceptibility of Human Carcinoma and Leukemia Cell Lines to Taxol Annals of the New York Academy of Sciences, 1996, 784, 550-554.	3.8	4
39	Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death. Cancer Chemotherapy and Pharmacology, 1995, 36, 385-392.	2.3	3
40	The Role of VL Gene Structural Determinants in the Fine Specificity of Anti-DNA Antibodies. Autoimmunity, 1994, 18, 227-227.	2.6	0
41	A novel 120-kDa antigen shared by immature human thymocytes and long-term-activated T cells. European Journal of Immunology, 1994, 24, 1-7.	2.9	15
42	The Role of VL Gene Structural Determinants in the Fine Specificity of Anti-Dna Antibodies. Autoimmunity, 1994, 18, 65-75.	2.6	7
43	Structural characterization of CD6: Properties of two distinct epitopes involved in T cell activation. Molecular Immunology, 1989, 26, 1037-1049.	2.2	37